Literature DB >> 25527980

A simple LC-MS/MS method using HILIC chromatography for the determination of fosfomycin in plasma and urine: application to a pilot pharmacokinetic study in humans.

Suzanne L Parker1, Jeffrey Lipman2, Jason A Roberts2, Steven C Wallis3.   

Abstract

A high performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) method, using hydrophilic interaction liquid chromatography (HILIC) chromatography for the analysis of fosfomycin in human plasma and urine, has been developed and validated. The plasma method uses a simple protein precipitation using a low volume sample (10 μL) and is suitable for the concentration range of 1 to 2000 μg/mL. The urine method involves a simple dilution of 10 μL of sample and is suitable for a concentration range of 0.1 to 10 mg/mL. The plasma and urine results, reported, respectively, are for recovery (68, 72%), inter-assay precision (≤9.1%, ≤8.1%) and accuracy (range -7.2 to 3.3%, -1.9 to 1.6%), LLOQ precision (4.7%, 3.1%) and accuracy (1.7% and 1.2%), and includes investigations into the linearity, stability and matrix effects. The method was used in a pilot pharmacokinetic study of a critically ill patient receiving i.v. fosfomycin, which measured a maximum and minimum plasma concentration of 222 μg/mL and 172 μg/mL, respectively, after the initial dose, and a maximum and minimum plasma concentration of 868 μg/mL and 591μg/mL, respectively, after the fifth dose. The urine concentration was 2.03 mg/mL after the initial dose and 0.29 mg/mL after the fifth dose.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antibiotic; Fosfomycin; HILIC; LC–MS/MS; Pharmacokinetic

Mesh:

Substances:

Year:  2014        PMID: 25527980     DOI: 10.1016/j.jpba.2014.11.042

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  5 in total

1.  Population Pharmacokinetics of Fosfomycin in Critically Ill Patients.

Authors:  Suzanne L Parker; Frantzeska Frantzeskaki; Steven C Wallis; Chryssa Diakaki; Helen Giamarellou; Despoina Koulenti; Ilias Karaiskos; Jeffrey Lipman; George Dimopoulos; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2015-08-03       Impact factor: 5.191

2.  Oral fosfomycin activity against Klebsiella pneumoniae in a dynamic bladder infection in vitro model.

Authors:  Iain J Abbott; Elke van Gorp; Kelly L Wyres; Steven C Wallis; Jason A Roberts; Joseph Meletiadis; Anton Y Peleg
Journal:  J Antimicrob Chemother       Date:  2022-04-27       Impact factor: 5.758

3.  Pharmacokinetics of fosfomycin in patients with prophylactic treatment for recurrent Escherichia coli urinary tract infection.

Authors:  Sander G Kuiper; Anneke C Dijkmans; Erik B Wilms; Ingrid M C Kamerling; Jacobus Burggraaf; Jasper Stevens; Cees van Nieuwkoop
Journal:  J Antimicrob Chemother       Date:  2020-11-01       Impact factor: 5.758

Review 4.  Determination and Identification of Antibiotic Drugs and Bacterial Strains in Biological Samples.

Authors:  Katarzyna Pauter; Małgorzata Szultka-Młyńska; Bogusław Buszewski
Journal:  Molecules       Date:  2020-05-31       Impact factor: 4.411

5.  Quantification of Fosfomycin in Combination with Nine Antibiotics in Human Plasma and Cation-Adjusted Mueller-Hinton II Broth via LCMS.

Authors:  Kelvin Kau-Kiat Goh; Wilson Ghim-Hon Toh; Daryl Kim-Hor Hee; Edwin Zhi-Wei Ting; Nathalie Grace Sy Chua; Farah Iffah Binte Zulkifli; Li-Jiao Sin; Thuan-Tong Tan; Andrea Lay-Hoon Kwa; Tze-Peng Lim
Journal:  Antibiotics (Basel)       Date:  2022-01-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.